At Acadia, our mission is to turn scientific promise into meaningful innovation that makes the difference for underserved neurological disorders and rare disease communities around the world. 

Our commercial portfolio includes FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. 

We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with early-stage programs that address other unmet patient needs.